Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Carcinoma, Anaplastic 4Neuroendocrine Tumors 4Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Adenocarcinoma, Follicular 2Wilms Tumor 1Vipoma 1Thyroid cancer, medullary 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Somatostatinoma 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Insulinoma 1Glucagonoma 1Gastrinoma 1Familial medullary thyroid carcinoma 1Differentiated Thyroid Cancer 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Everolimus 4Leucovorin 3vatalanib 2pentetreotide 2Trastuzumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Cisplatin 2Bortezomib 2Biological Therapy 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pazopanib 1motesanib diphosphate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Thalidomide 1Streptozocin 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Sorafenib × Endocrine × Clear all
NCT00131911 2014-11-17

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Completed
93 enrolled 10 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡